Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00047476 | D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients | PHASE2 | COMPLETED | 160 | — | — | Jun 1, 2002 | Mar 1, 2004 | Jun 24, 2005 | 21 | United States |
| Name | Type | Description |
|---|---|---|
| dexmethylphenidate(d-mph) | DRUG | - |
* Diagnosis of cancer, excluding primary or metastatic brain tumors. * Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry. * Physical/neurological examination consistent with the absence o...